In the field of medicine，Innovation is an eternal theme。From imitation、Imitation is combined to innovate like a pyramid，The bottom -level generic drug manufacturer will always face low profits、Fierce competition; and the innovative medicine in the top level，Then you can get high profits。Facing the attractive market & ldquo; cake & rdquo;，The world's main pharmaceutical powers are accelerating the pace of innovative drug development。

 

  As the second largest pharmaceutical market in the world，Among the chemicals produced by thousands of pharmaceutical companies in my country，Imitation drugs are more than 95%。With pharmaceutical companies pay more and more attention to the development of innovative drugs，The proportion of R & D investment is getting larger and larger，Chinese innovative drugs have come to an important mark facing breakthroughs。

 

  Increase R & D investment

 

  Recently，Two multinational mergers and acquisitions in the domestic pharmaceutical industry have set off a wave of waves in the industry: July 26，Green Leaf Pharmaceutical Group announced signing with Switzerland ACINO Company，Buy its transparent release system and implant business for 245 million euros; July 28，Fosun Pharmaceutical Release Announcement，It is planned to acquire about 86.08%equity of Gland Pharma Limited India，This is the largest overseas M & A case in Chinese pharmaceutical companies.。

 

  Increase mergers and acquisitions in the field of overseas pharmaceuticals，has become a Chinese pharmaceutical company to improve the level of research and development、Accelerate the important efforts to moving towards the international market。Related persons of Green Leaf Pharmaceutical Group pointed out，Acquisition such a My stake betting appEuropean stake sports betting appcompany business with a leading professional level in the subdivided field，It will greatly improve the research and development and production of green leaf pharmaceuticals in the field of new preparations、International registration、International level of marketing and other aspects，Help further develop the global market。Chairman of Fosun Pharmaceutical Chen Qiyu said，The resource grafting of the two pharmaceutical companies in China and India will help promote the internationalization pace of Chinese pharmaceutical companies in R & D innovation and generic drug exports。

 

  Dested，Green leaf medicine、Fosun Pharmaceutical and Hengrui Pharmaceutical、Pharmaceutical companies represented by Tzuhili, etc.，The first echelon & rdquo;。Green Leaf Pharmaceuticals currently have patented products that account for more than 80 % of the total income，and have a rich research product line; & ldquo; Twelve Five -Year Plan & rdquo;，Fosun Pharmaceutical's R & D investment has exceeded 2 billion yuan; as of now，Hengrui Medicine has undertaken 4 national 863 major science and technology special，22 projects are included in the national & ldquo; major new drug creation & rdquo; special，More than 200 invention patents have been applied for，Among them, 100 global patents (PCT patents); Tasses is a representative of modern Chinese medicine。Introduction of Sun He, vice president of Tazhi Holding Group，After nearly 20 years of hard work，Tzuhiki Fang Danshen Di Wan has successfully completed the third phase of the US FDA clinical trial，Enter data statistics and new drug declaration preparation stage。Once the registration is successful，It will become the world's first compound Chinese medicine product registered in the United States FDA。

 

  Ten years grind a sword。With the rapid development of the Chinese pharmaceutical industry，A group of local pharmaceutical companies represented by the first echelon & rdquo;。From the perspective of R & D investment，Although domestic enterprises are far from the total R & D investment, it is far from multinational pharmaceutical companies，But in recent years, R & D investment has grown rapidly，Strong momentum。Statistics display，2015，Eight companies with higher domestic R & D investment have increased investment in R & D investment exceeding 20%，Hengrui Medicine、Fosun Medicine、Haizheng Pharmaceutical R & D investment exceeds 800 million yuan，Catching up some of the global top 50 China -prescription drug sales companies。From the perspective of R & stake sports betting Stake Sports BettingappD investment accounting for sales income，Hengrui Medicine、Haizheng Pharmaceutical and other companies have reached or nearly 10%，More than some of the world's top 50 medium -made drug companies。

 

   & ldquo; If 10 years later China becomes an important source of innovation in medicine，I won't be surprised。& rdquo; Luke Miels, Vice President of Astrikon Global Product Portrait and Product Strategy, said。

 

  Looking for a breakthrough path

 

  Innovative drugs refer to drugs with independent intellectual property patents。Industry insiders know，Innovative drugs are long from the project to the approved listing of the drug supervision department.、full of risks、Expensive process，Generally requires a cycle of 10 to 20 years and about $ 1 billion in funds; and 10,000 in the new medicine，There may be only 10 clinical clinical，The real sales can exceed 1 billion US dollars & ldquo; heavy bombs & rdquo; then there may be only 1。On the other hand，Because the protection period of innovative drug patent can be up to 20 years，Once the new medicine is successful，Often the company's stock price skyrocketed，Make a lot of money。

 

  Due to the power of research and development、Fund input and new drug reserves are still quite different from the multinational pharmaceutical giants，China's innovative drug research and development is still in its infancy。10 drugs with the highest global sales in 2015，All are developed and produced by multinational pharmaceutical companies。How to go to the development of Chinese innovative drugs? Industry experts think，It should be based on national conditions，Looking for a breakthrough way suitable for the status of Chinese pharmaceutical companies。In this regard，The experience of some domestic companies may provide useful revelation。

 

  Fosun Pharmaceutical Company continues to improve & ldquo; Pharmaceutical R & D system，In the small molecular chemistry innovation medicine、Similar medicines of macromolecules、High -value generic drugs、Special preparation technology and other fields created an efficient R & D platform。President and chief operating officer of Fosun Pharmaceutical, Wu Yifang, introduced，Fosun Pharmaceutical R & D Innovation Development will be divided into three stages: recent，It will focus on creating innovation capabilities，Including talent architecture、Infrastructure supporting、The construction of clinical ability, etc.; Mid -term，The path of & ldquo; imitation & rdquo;，will become a completely innovative enterprise，Strive after 10 to 15 years，Most of the income of Fosun Pharmaceutical driven by innovation drive。

 

  Stake Sports Bettingstake online sports bettingIn recent years，505 (b) (2) path for the new US FDA new drug application is becoming more and more valued in the field of new drug research and development。This path can be applied to two types of declarations，One is a new chemical molecule，The other is the change of the approved drugs，Including indications、Formula、Dosage form、Drug pathway、medication plan, etc.。Former Chairman of the American Traditional Chinese Medicine Development Association、Dr. Xu Zhixin, a senior director of Pharmaceutical Pharmaceutical, believes，For Chinese pharmaceutical companies，The use of 505 (b) (2) path is a practical and feasible choice。He said，505 (b) (2) Avoid repeating unnecessary tests that have been proven，Make R & D enterprises not only save funds、Accelerate the process of drug listing，You can enjoy the market return brought by new drugs，It is a high successful power、Low -risk research and development strategy。

 

  Industry experts proposed，For Chinese pharmaceutical companies currently based on generic drugs，To improve competitiveness，There are two ways to try: First, choose some difficult products to overcome，Let the competitors retreat; the second is to challenge the lower technical barriers 505 (b) (2) Product，Once successful，It can not only form professional advantages on certain products，The exclusive rights obtained at the same time also avoided the competition of peers。

 

  Enterprises have set up R & D centers and related institutions in the United States，Accelerate international exchanges and cooperation，Flected a set of & ldquo; Chinese and foreign binds，How fast is good to save & rdquo; international project mode management，Registration for Chinese pharmaceutical products in Europe and the United States、Sales created a new road。

 

  Do a good job of top -level design

 

  Due to the particularity of the development of innovative drugs，From basic research、Enterprise R & D、Clinical Test、New drug registration to marketing，Is a long and complex chain，Involved in scientific research institutes、For this、Government、Hospital and other links。For this，Expert proposed，We must firmly grasp the new trend of international innovative drug development，Alliances for establishing political, industry -research and research，Starting from the actual situation of our country, do a good job of top -level design。

 

  Innovative drug development，The most important thing is to have a good policy environment。Wu Haidong, deputy director of the Consumer Industry Department My stake betting appStake Sports Bettingof the Ministry of Industry and Information Technology, proposed，The pharmaceutical industry should enhance innovation capabilities during the period of the pharmaceutical industry in the period of & ldquo;，First, increase investment，Second, improve efficiency，Actively promote the strategic transformation of our country from tracking to imitation and imitation of independent innovation。

 

  Introduction to Wu Haidong，The first key task proposed in the pharmaceutical industry & ldquo; 135 & rdquo;。The first is to promote product innovation，Increase the development of original drugs，Realizing drug research and development from imitation to creation and upgrading，To meet the needs of major clinical diseases in my country; the second is to build a platform，Construction of Drug Medical Device Innovation Center，Carry out key common technology around the development of the industry，Breakthrough industrialized technical bottleneck，Promoting the transformation of innovation results; third, support the development of small and medium -sized innovative enterprises，Building an innovative and entrepreneurial service platform，Implementation of the pharmaceutical industry venture capital plan，Support a group of small enterprises engaged in new drug innovation，Make it an important source of medical innovation in my country。

 

  top -level design+policy support+cooperation alliance，The road to new drugs with Chinese characteristics is actively exploring。